Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Acute, Affective, Organic Disorders.
This study has been completed.
Sponsors and Collaborators: Norwegian University of Science and Technology
St. Olavs Hospital
Dr. Dedichens Institute for Psychiatric Research, Oslo, Norway.
GlaxoSmithKline
Information provided by: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00201474
  Purpose

The purpose of the study is to investigate wether patients with brief depressive periodes together with other fluctuating psychiatric symptoms, have this condition due to epilepsy or an other organic brain disorder.


Condition
Acute Psychiatry
Depressive Disorders

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy
MedlinePlus related topics: Brain Diseases Depression Epilepsy
U.S. FDA Resources
Study Type: Observational
Study Design: Psychosocial, Longitudinal, Convenience Sample, Prospective Study
Official Title: Signs of Organic Brain Dysfunction in Psychiatric Patients With Fluctuating Psychiatric Symptoms Including Brief Depressions Compared to Patients With a Major Depressive Episode.

Further study details as provided by Norwegian University of Science and Technology:

Estimated Enrollment: 30
Study Start Date: October 1998
Estimated Study Completion Date: October 2004
Detailed Description:

A limited number of patients admitted to psychiatric acute wards or Psychiatric Intensive Care Units are admitted with a fluctuating array of psychiatric symptoms including brief depressive episodes. These patients do not fit into the present diagnostic systems due to short duration of affective symptoms and the flucuating arrays of other symptoms. Case histories indicate that these patients have psychiatric conditions due to epilepsy or organic brain dysfunctions.

In the study acutely admitted patients filling criteria for two recent DSM-4 axis 1 diagnoses (one is a brief depressive period) during the last two weeks are compared to age- and sex-matched patients acutely admitted with a major depressive disorder. The patients are rated with a number of rating scales at admittance, day 5, after two weeks and three months. EEG and QEEG are taken three times the first week. MRI, drug screening and blood screening of medication-consentrations are taken.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acutely admitted psychiatric patients who have at different times the last 2 weeks filled criteria for at least two new DSM-4 Axis 1 psychiatric diagnoses. One of them has to be a depressive episode (MADRS>20)

Exclusion Criteria:

  • Patients not speaking Norwegian or English.
  • Patients not willing to participate.
  • Patients with dementia or mental retardation to an extensive degree.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00201474

Locations
Norway
Østmarka Psychiatric Department, St. Olavs Hospital
Trondheim, Norway, 7441
Sponsors and Collaborators
Norwegian University of Science and Technology
St. Olavs Hospital
Dr. Dedichens Institute for Psychiatric Research, Oslo, Norway.
GlaxoSmithKline
Investigators
Study Chair: Olav M Linaker, Professor Norwegian University of Science and Technology
  More Information

Study ID Numbers: AEV-98
Study First Received: September 16, 2005
Last Updated: September 16, 2005
ClinicalTrials.gov Identifier: NCT00201474  
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
brief depressive episodes
affective disorders
EEG and QEEG
epilepsy
organic brain disorders

Study placed in the following topic categories:
Depression
Mental Disorders
Epilepsy
Mood Disorders
Depressive Disorder
Brain Diseases
Behavioral Symptoms

Additional relevant MeSH terms:
Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 16, 2009